IMMUNEONCO-B: The first patient has been dosed in the Phase IB/II clinical trial of IMM2510 in combination with IMM01

According to the Zhitong Finance APP, IMMUNEONCO-B (01541) announced that the Phase IB/II clinical trial of IMM2510 combined with IMM01 for the treatment of advanced solid tumors has successfully completed the first patient dosing, marking a milestone achievement for the group in the field of innovative cancer immunotherapy. IMM2510 (Pervirapimab α) is independently developed by the group and is a bispecific molecule targeting vascular endothelial growth factor (VEGF) and programmed cell death ligand 1 (PD-L1), utilizing a monoclonal antibody-receptor recombinant protein (mAb-Trap) structure. IMM2510 can inhibit angiogenesis, reduce tumor size, and make tumor cells more sensitive to immune responses, while activating T cells, natural killer cells, and macrophages by blocking the PD-L1/programmed cell death protein 1 (PD-1) interaction and inducing Fc-mediated antibody-dependent cellular cytotoxicity (ADCC)/antibody-dependent cellular phagocytosis (ADCP) activity. The company has entered into a licensing and collaboration agreement with Axion Bio, Inc. (formerly known as SynBioTx Inc., a wholly-owned subsidiary of Instil Bio, Inc. (NASDAQ: TIL)), under which the company holds the commercialization rights for IMM2510 (Pervirapimab α) in the Greater China region (including mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, and Taiwan) and agrees to grant Axion Bio, Inc. exclusive rights to research, develop, and commercialize IMM2510 (Pervirapimab α) outside the Greater China region. The group's core product IMM01 (Tidalimab) is an innovative molecule targeting CD47. This product is the first SIRPα-Fc fusion protein to enter clinical stages in China. IMM01 (Tidalimab), with immunoglobulin G1 (IgG1) Fc, can fully activate macrophages through a dual mechanism—blocking the "don't eat me" signal by interfering with the CD47/SIRPα interaction and delivering the "eat me" signal by activating macrophage Fc-gamma (Fcγ) receptors. Additionally, the CD47 binding domain of IMM01 (Tidalimab) has been specially modified to avoid binding with human red blood cells (RBCs). With differentiated molecular design, IMM01 (Tidalimab) demonstrates good safety and confirms its ability to activate macrophages. IMM01 (Tidalimab) combined with azacitidine for first-line treatment of CMML received orphan drug designation from the U.S. Food and Drug Administration (FDA) in November 2023. The group holds global intellectual property and commercialization rights for IMM01 (Tidalimab). As of the date of this announcement, the group has a patent family for IMM01 (Tidalimab), which includes granted patents in China, the United States, Japan, and the European Union